Researchers evaluate these pathways with biomarkers, brain imaging, and clinical scales to determine whether a compound brings meaningful clinical benefit.
Mei’s mind raced. “The Repository—” ALDN-084
Kinome profiling (DiscoverX KINOMEscan™ 400‑panel) demonstrates > 95 % inhibition of IKKβ at 100 nM with < 10 % off‑target activity against IKKα, TBK1, or JNK1/2. Researchers evaluate these pathways with biomarkers